In most mature cannabis plants, the CBG content remains very low, often below 1% of dry matter. This rarity is explained by the plant's biochemistry: CBG exists primarily in its acidic form, CBGA, which serves as a precursor to other cannabinoids. Only certain cultivars selected for their CBG-dominance, or harvested early, significantly exceed this threshold.
In short:
- The CBG content in a mature plant rarely exceeds 1%, except in selected or early-harvested cultivars, due to CBGA consumption during biosynthesis.
- A CBG level above 1% requires precise laboratory analysis, favoring LC-MS/MS chromatography and recent certification.
- Achieving an active effect of 20 to 50 mg of CBG often requires the use of concentrated extracts, as the natural level in the flower is not sufficient.
- Cultivation, early harvesting and genetic selection are levers to maximize CBG levels, but biochemical variability makes a homogeneous result impossible.
- The stability of CBG over time depends on storage conditions, which must reduce exposure to light, heat and oxygen to prevent degradation.
Table of Contents
- Why CBG concentration drops at maturity: the role of CBGA
- What CBG levels are actually being measured, and why do they vary so much?
- How to read an analysis report and identify a reliable CBG level
- From the concentration in the plant to the active dose: what pharmacokinetics changes
- Precautions to know before increasing your CBG intake
- What regulatory framework governs CBG-based products?
- Does the growing environment really change the CBG level?
- Does storage alter the CBG content over time?
- Oils, flowers, isolates: where can you find the most concentrated CBG?
- Does the concentration of CBG really determine the effect felt?
- Can the CBG level in culture be increased?
- What the CBG figures really reveal
- Choose a CBG-based product with a verifiable level
- Links and studies cited
- Sources
- Frequently Asked Questions
Why CBG concentration drops at maturity: the role of CBGA
The CBG found in a dried flower is almost never the same as that present in the living plant from the start. It all begins with CBGA, cannabigerolic acid, considered the parent molecule of cannabinoid biosynthesis. Specific enzymes, synthases, then transform this precursor into tetrahydrocannabinolic acid (THCA), cannabidiolic acid (CBDA), or cannabichromenic acid (CBCA), depending on the plant's genetic makeup.
This enzymatic conversion intensifies as the plant progresses towards full flowering. As a result, the later the harvest, the more of the available CBGA has been consumed by these synthases, and the lower the final CBG concentration measured in the dried flower will be.
In practical terms, this means that the harvest schedule acts as a direct lever on the final CBG level:
- An early harvest, before complete enzymatic conversion, preserves a larger proportion of untransformed CBGA.
- A late harvest generally maximizes THCA or CBDA levels, but depletes the CBG reservoir.
- Cultivars genetically selected to block or slow this conversion display atypical CBG-dominant profiles.
What CBG levels are actually being measured, and why do they vary so much?
Laboratory analyses confirm what biochemistry suggests: the CBG content in a mature flower rarely exceeds 1% of dry matter, except in cases of genetic exception. Cultivars specifically developed to be CBG-dominant can exhibit significantly higher levels, sometimes several percentage points higher, but they remain a minority on the market.
Several factors explain the difference between two batches from the same species:
- The genotype: some lines carry a mutation that partially blocks the conversion of CBGA, which naturally preserves a higher level of CBG.
- The harvest stage, already mentioned, remains the most easily observable and controllable factor.
- Cultivation practices: planting density, pruning, light management.
- Abiotic stress (drought, temperature variations), which can disrupt enzymatic activity irregularly.
It is also important to distinguish between two often confused measurement scales: the percentage on a dry plant matter basis, which describes the plant's composition, and the plasma concentration in nanograms per milliliter, which describes what the body absorbs after consumption. These are two different units, with no direct conversion between them.
How to read an analysis report and identify a reliable CBG level
Interpreting a laboratory analysis (COA, for certificate of analysis) requires some simple but essential technical guidelines to avoid overinterpreting a number.
- Check the analytical method used. Liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) remains the reference for accurately quantifying cannabinoids, including their acidic forms; gas chromatography (GC) is sometimes used but can thermally convert acidic forms to neutral forms, which distorts the reading of the true CBGA.
- Check if a hydrolysis step has been applied. This reveals the total content of acidic cannabinoids, without which the displayed CBG level may underestimate the actual amount.
- Look at the limit of quantification (LOQ). A result close to this limit warrants careful interpretation: the relative margin of error is mechanically higher.
- Confirm the laboratory accreditation and the date of analysis. A CBG level measured on a batch several months old does not necessarily reflect the product delivered today.
From the concentration in the plant to the active dose: what pharmacokinetics changes
A CBG level of 1% in a dried flower seems anecdotal, and it often is in practice: to reach the active doses tested in research, most consumers have to turn to concentrated extracts rather than raw flower, as the natural quantities remain low.
A double-blind clinical trial conducted in 2024 showed that a single 20 mg dose of CBG significantly reduced self-reported stress and anxiety in 34 adults, without producing psychoactive effects, with a 26.5% decrease in anxiety levels measured on a visual analog scale. This study remains one of the few to quantify a measurable effect of CBG in humans, but it focuses on a single dose, not chronic use.
This figure of 20 mg puts into perspective the difference between the raw plant and the finished product: reaching an active dose of 20 to 50 mg of CBG generally requires consuming an extract whose concentration has been deliberately increased compared to the natural rate of the flower.
Furthermore, the oral bioavailability of CBG remains limited, which is prompting formulators to work on the product format:
- Taking the drug with a high-fat meal significantly increases the maximum plasma concentration (Cmax) and total exposure (AUC) compared to taking it on an empty stomach.
- Lipid emulsions or fatty excipients integrated directly into the formulation (oils, capsules) aim to reproduce this effect without depending on the content of the meal.
- The inhaled route reaches its maximum plasma concentration in about ten minutes (Tmax ≈ 0.17 h), while the oral route has a half-life of 2 to 6 hours, which explains the very different action profiles depending on the format chosen.
Precautions to know before increasing your CBG intake
CBG, like other cannabinoids, can interact with certain liver enzymes of the CYP group, the same enzymes that metabolize many medications. A medical consultation is recommended before regular use if you are undergoing treatment, especially at concentrated doses.
A few simple precautions can help avoid unpleasant surprises:
- Always demand a recent certificate of analysis, carried out by an accredited laboratory.
- Check that the product complies with the regulatory THC limit applicable in your country.
- Start with a low dose and observe your body's response before gradually increasing it.
Clinical trial registries list several ongoing studies on CBG, a sign of growing scientific interest, but available human data remain limited to date.
What regulatory framework governs CBG-based products?
CBG itself is not classified as a narcotic under European regulations, unlike THC above certain thresholds. It is the THC content of the finished product, and not the CBG level, that determines its legality in almost all European markets.
The regulations applicable in France and the European Union set a tolerance of 0.3% THC in hemp extracts intended for commercial sale. This threshold applies to the finished product, not to the raw plant in the field, a distinction often overlooked by new consumers. A CBG-based product can therefore have a high CBG content while remaining perfectly compliant, as long as its THC level remains below this limit.
This conformity must be demonstrated by an independent laboratory analysis, included with the product or accessible via a viewable certificate. The absence of this document, or a document whose date or method of analysis is not specified, constitutes a warning sign for the buyer.
A reader who buys or transports a CBG-based product should therefore check the regulations specific to their country of residence, as European compliance does not automatically guarantee legality elsewhere.
Does the growing environment really change the CBG level?
Light, temperature, and humidity influence the activity of synthases responsible for CBGA conversion, and therefore indirectly the amount of CBG remaining at harvest. Poorly managed light or heat stress disrupts the plant's secondary metabolism, which can slow down or unbalance this enzymatic conversion in unpredictable ways.
Intense and prolonged light exposure during the flowering phase tends to accelerate plant maturation, which also speeds up the conversion of CBGA to THCA or CBDA, and consequently reduces the window during which CBG remains available in significant quantities. Growers seeking to maintain a higher CBG level sometimes adjust the photoperiod to slightly delay this maturation, without, however, guaranteeing consistent results from one cycle to the next.
Relative humidity, on the other hand, influences the quality of post-harvest storage more than biosynthesis itself, but excess humidity during flowering also promotes the development of molds that compromise the entire harvest, including CBG.
These three parameters therefore act in interaction rather than in isolation, which explains why two crops of the same cultivar, grown in different environments, can display measurably distinct CBG levels at harvest time.
Does storage alter the CBG content over time?
A CBG level measured at harvest is not static: exposure to light, heat, and oxygen during storage gradually degrades cannabinoids, including CBG. This degradation follows a known chemical logic: oxidation and photodegradation slowly transform cannabinoid molecules into degraded compounds, reducing the available active concentration over time.
Storing it away from light, in an airtight container and at a stable temperature, significantly slows down this loss.
This reality has a direct practical consequence for the buyer: a Certificate of Analysis (COA) remains representative only if the product has been stored under conditions comparable to those of the laboratory at the time of testing, and only for a reasonable period after analysis. A batch analyzed several months before purchase, without clear indication of storage conditions, warrants a cautious interpretation of the stated percentage. This is why the date of analysis is among the criteria to be systematically verified on a certificate, along with the method used and the laboratory's accreditation.
Concentrated extracts (oils, resins) generally have better stability than raw flowers, as plant matter is more exposed to ambient oxygen than formulations packaged in closed bottles.
Oils, flowers, isolates: where can you find the most concentrated CBG?
The product format directly determines the amount of CBG accessible to the consumer, far more so than the original cultivar alone. Raw flowers, even from CBG-dominant cultivars, generally have a CBG content capped at a few percentage points on a dry matter basis, which remains modest compared to what an extraction process can concentrate.
Oils obtained through extraction, particularly with supercritical CO2 or solvents, allow for the selective concentration of cannabinoids present in the starting biomass, while removing some of the inert plant matter. The final concentration depends directly on the richness of the plant material used upstream: extracting a plant low in CBG will never produce an oil rich in CBG, regardless of the sophistication of the process.
This level of purity facilitates precise dosing, but also eliminates interactions between cannabinoids that some formulators intentionally seek in so-called broad-spectrum products.
Between these two extremes, resins and broad-spectrum extracts display intermediate levels, often shown as a percentage on the label, which directly reflect the concentration of the extraction process rather than the natural concentration of the original plant. Therefore, comparing two products requires comparing their category before comparing their stated percentages.
Does the concentration of CBG really determine the effect felt?
The applications explored for CBG—stress reduction, sleep support, digestive comfort—depend directly on the active dose received, and therefore on the concentration of the product consumed, much more so than on its mere presence. A product with a negligible CBG content cannot reasonably deliver the effect documented by a study conducted with a single 20 mg dose.
Human clinical data on CBG exist, but they are still limited : the anxiolytic and relaxing effect is currently the best documented by a controlled clinical trial, while other benefits often mentioned, such as possible cognitive support, are based mainly on preclinical observations or testimonials, without equivalent clinical validation.
Reading the label in milligrams per dose, and not just in percentage, remains the most reliable guide to anticipate an effect consistent with the doses studied in clinical research.
Can the CBG level in culture be increased?
Growers have several agronomic levers to maximize the CBG content of a harvest, the most direct being the genetic selection of naturally CBG-dominant cultivars, carrying a mutation that limits the enzymatic conversion of CBGA to other cannabinoids.
The second, complementary lever involves precisely adjusting the harvest schedule: an early harvest, before the synthases have converted the majority of the available CBGA, preserves a higher CBG level, often at the cost of a slightly lower overall biomass or terpene yield. This trade-off between yield and content remains central to agronomic choices in this sector.
Other cultivation practices, such as planting density, nutrient management, and photoperiod control, influence the final result to a lesser extent, but can be combined with the two main levers to further refine the yield. However, none of these techniques guarantees identical results from one cycle to the next, as natural biological variability remains a difficult component to eliminate completely, even under controlled growing conditions.
What the CBG figures really reveal
The most common misconception surrounding CBG is that its status as a "mother molecule" is equated with a supposed natural abundance. The opposite is true: the further a plant matures, the less CBG it contains, as it is converted into other cannabinoids. This biochemical scarcity explains why almost all effective CBG products rely on deliberate extraction and concentration, never on simply consuming raw flower.
This observation calls for a more rigorous reading of labels and certificates of analysis. A percentage displayed without a specified analytical method, a recent date, or mention of laboratory accreditation makes it impossible to know what the consumer is actually receiving. Thefrenchhempempire relies on independent laboratory analyses and verifiable traceability for each product offered, a requirement that becomes crucial when dealing with cannabinoids as naturally low in concentration as CBG.
To delve deeper into the issue of perceived dosage, our article on the effects of a 20 mg dose of CBG details the practical guidelines from recent clinical research.
— Vanessa
Choose a CBG-based product with a verifiable level
Given such low natural levels, the real question isn't finding CBG, but finding a product whose concentration has been measured, documented, and maintained until sale. Some online shops offer oils, resins, and flowers with controlled cannabinoid content, each accompanied by a certificate of analysis allowing you to verify the actual level before purchase, rather than relying on marketing claims on packaging.
Our page dedicated to high-concentration products details these criteria, as does our comparative guide on the differences between CBG, CBN, and CBD, to help you determine which cannabinoid best suits your needs. Consult these pages to compare the advertised concentrations before placing your order.
Links and studies cited
- 2024 Clinical Trial on the Acute Effects of CBG
- CBG blood biomarker (PubMed, 2023)
- Pharmacology and metabolism of CBG
- Impact of dietary fats on the pharmacokinetics of CBG
This article provides general information and is not a substitute for professional medical advice. Consult a qualified healthcare professional about your specific situation before taking any action based on this content.
Sources
- Acute effects of cannabigerol on anxiety, stress, and mood: a double-blind, placebo-controlled, crossover, field trial – PMC
- PubMed reference (2023) — CBG blood biomarker
- Pharmacological Aspects and Biological Effects of Cannabigerol and Its Synthetic Derivatives – PMC
Frequently Asked Questions
Is CBG stronger than CBD?
CBG is not "stronger" in the strict sense: it acts on biological targets that are partly different from CBD, with a documented anxiolytic effect from 20 mg in a recent clinical trial, but overall less human data than that available for CBD.
What are the effects of CBG?
The best-established clinical effect is a reduction in perceived stress and anxiety, without psychoactive effects, observed after a single 20 mg dose in a controlled trial. Other reported effects, such as possible support for sleep or digestive comfort, are based primarily on preclinical observations.
What are the dangers of CBG?
The main point of concern relates to potential interactions with certain liver enzymes (CYP), which are relevant in the case of ongoing drug treatment. Choosing a product with a current certificate of analysis and starting at a low dose remains the best way to limit risks.
Can CBD improve mental concentration?
Clinical evidence of a direct effect of CBD or CBG on cognitive focus remains limited and is primarily based on preliminary observations rather than robust trials. However, the 2024 clinical trial reported an improvement in verbal memory after a 20 mg dose of CBG, a finding that warrants confirmation through larger studies.
